AdreView Approved for Visualization of Myocardial Sympathetic Innervation

AdreView is the first and only imaging agent approved for visualization of myocardial sympathetic innervation in certain heart failure patients

 

March 22, 2013
FDA Approval GE Healthcare's AdreView Nuclear Imaging SPECT systems

AdreView (Iobenguane I 123 Injection) is the first and only FDA approved molecular imaging agent to link nerve function in the heart to a patient’s mortality risk. AdreView is approved for the scintigraphic assessment of myocardial sympathetic innervation (cardiac nerve activity) to assist in the evaluation of patients with New York Heart Association (NYHA) Class II or Class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35 percent.

AdreView uses the heart to mediastinum (H/M) ratio to assess the functionality of the sympathetic nerves. With AdreView, the H/M ratio is a measure of radioactivity uptake in the heart compared to that of a reference region in the mediastinum (the mass of tissues and organs between the two pleural sacs that separate the heart from the lungs). This measurement has a typical range of 1-2.4 and can accurately identify patients with lower than average one- and two- year mortality risk. 

For more information: newsroom.gehealthcare.com

 

 

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.